Cephelon Beats Estimates, Raises Guidance, Sells Off

Biopharmaceutical company Cephalon ( CEPH) posted a second-quarter profit on higher-than-expected sales Monday after the close, as total company revenue increased 115% from the year-ago quarter.

Cephalon said it earned $14.4 million, or 25 cents a share, in the quarter, compared with a year-ago loss of $9.3 million, or 19 cents a share, excluding an extraordinary gain. Analysts polled by tracking firm Thomson Financial/First Call had been looking for 21 cents.

Despite the solid results, shares were recently down about 5% to $40.75 in premarket trading.

Total revenue was $120.7 million, up from $56.2 million last year and ahead of the consensus estimate of $111.68 million. Total product sales were $108.8 million, up from $44.3 million last year, led by sales of cancer painkiller ACTIQ, which increased 192% to $28.5 million.

Looking ahead, the company raised its full-year guidance on the "exceptionally strong sales of ACTIQ," saying it now expects to earn $1.08 to $1.10 a share on product sales of $430 million to $435 million. Previously, Cephalon had forecast $1.05 to $1.08 a share on sales of $415 million to $420 million.

For the third quarter, the company expects to earn 27 cents a share on sales of $110 million to $115 million.

First Call analysts are looking for $1.08 for the year and 27 cents for the third quarter.

More from Technology

Facebook Takes Aim at YouTube, But It'll Be an Uphill Online Battle

Facebook Takes Aim at YouTube, But It'll Be an Uphill Online Battle

Microsoft Chief Says Its ICE Contract Isn't Part of Child Separation Policy

Microsoft Chief Says Its ICE Contract Isn't Part of Child Separation Policy

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio